All News

Excessive dietary sodium intake is linked to increased prevalence and severity of atopic dermatitis (AD).

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.

Patients with HIV who were more impacted by health disparities were less likely to find long-acting injectable antiretroviral therapy appealing.

A dose escalation strategy for regorafenib could improve the cost-effectiveness of the medication in metastatic colorectal cancer (CRC).

The low-calorie sweetener was associated with incident major adverse cardiovascular event risk, according to one study.

Continuing with our Pride Month podcast series, in this episode we speak with Perry Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, and James F. Dougherty, VMD, MS, current member of Rutgers' Board of Governors.

The approval brings a new treatment option to pediatric patients with polyarticular juvenile idiopathic arthritis, which is a form of arthritis affecting multiple joints at the same time.

Medicare Advantage plans can implement 3 simple steps to make sure that they are competitive in the modern Stars environment.

Eli Lilly’s Alzheimer disease drug donanemab unanimously earned the backing of FDA advisers; recent research found 323 active drug shortages in the first 3 months of 2024, marking the highest number since 2001; Microsoft and Google will offer free or discounted cybersecurity services to US rural hospitals to make them less vulnerable to cyberattacks.

Building on prior research, a team tackled mouse-model colon cancer with a novel nonviral nanovector to carry dual–messenger RNA (mRNA) immunogene therapy.

Melissa Jones, MD, shares insights into recent artificial intelligence (AI) innovations in the realm of sleep studies.

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).

Metformin showed promise for improving the overall survival rate of patients with melanoma; however, this result may be an indirect consequence of the drug.

The 2024 European Hematology Association (EHA) Congress, convening virtually and in Madrid, Spain, from June 13-16, 2024, will feature practice-changing findings in hematology and oncology, as well as ample networking opportunities and conversations about the future of the field.

Scalp-cooling therapy (SCT) is a treatment that may help reduce hair loss in women with breast cancer who are experiencing chemotherapy-induced alopecia (CIA). A study found that many women who used SCT were satisfied with the results, but the treatment is expensive, making it necessary for more advocacy by health care professionals to make SCT accessible.

Uninsured rates among minority groups plummeted between 2010 and 2022; Democrat lawmakers are challenging drug patents that they believe are deliberate attempts to eliminate low-cost, generic competitors; the National Institutes of Health (NIH) is piloting a nationwide network for primary care research.

There may be a causal relaPatients with hyperthyroidism are at increased risk of ovarian cancer (OC), although the link between the conditions is not yet fully understood.

Although further research is needed, these new findings suggest that using the 2 intranasal sprays is an effective option for patients with myasthenia gravis (MG) who experience eyelid drooping.

This week, the Center on Health Equity and Access covered the release of the best US hospitals for equitable access, news from the CMS Health Equity conference, biomarker testing legislation, and insights on improving access for queer communities and the disparities in dermatology.

The data come from the observational Cost of Hemophilia in Europe: A Socioeconomic Survey II (CHESS II) study of 288 Spanish patients with hemophilia A and B, which showed certain differences between disease subtypes but overall similar trends in disease impact.

Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.

During the CMS Health Equity conference, the “Implementing Health Equity Through Value-Based Care for People in Medicare” session featured a series of expert speakers who shared insights on pioneering strategies designed to advance health equity.

Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study.

Initiatives that encourage or mandate collecting LGBTQ+ data could provide a plethora of benefits for clinicians and health care providers, from identifying disparities to creating stronger, more trusting relationships between LGBTQ+ patients and the health care system.

Having a higher magnesium depletion score (MDS) independently predicts increased all-cause and cardiovascular mortality risks in US patients with hypertension (HTN), emphasizing the importance of early HTN prevention and magnesium deficiency management.

A small cohort demonstrated the potential benefits aerobic exercise regimens hold for managing fatigue symptoms in multiple sclerosis (MS), but more studies are needed.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses an ongoing trial and novel development in plasminogen deficiency type 1.

Going forward, the federal government must pay potentially hundreds of millions more to underfunded Native American tribes with health care programs; the FDA reversed its ban on Juul e-cigarettes yesterday as it reviews new court decisions and updated information; hospitals nationwide are experiencing workforce shortages as doctors and nurses increasingly leave the field.

An abstract presented at the 2024 American Society of Clinical Oncology annual meeting showed that patients treated with zanubrutinib or acalabrutinib had more favorable safety and efficacy outcomes.